engleski

Comparison of MAGE –A3/4 and NY-ESO1 expression with prognostic markers in chromophobe renal cell carcinoma and renal oncocytoma

The cancer-testis family of antigens is expressed in a variety of malignant tumors. They are not expressed in normal human tissues, except for the testis. Expression of two genes from this family, MAGE-A3/4 and NY-ESO1, has been described in different malignant tumors such as melanomas, germ cell tumors, and uterine neoplasm. To our knowledge, there are no studies on the expression of these genes and their proteins in renal tumors. The aim of this study was to investigate the expression of MAGE-A3/4 and NY-ESO1 in renal oncocytomas (RO) and chromophobe renal cell carcinomas (CRCC) detected by immunohistochemistry and to compare the expression of MAGE-A3/4 and NY- ESO1 with other prognostic markers (size, grade) in CRCC. A total of 35 patients (17 RO and 18 CRCC) treated at Sestre milosrdnice University Hospital and Dubrava University Hospital were included. Monoclonal antibodies for MAGE-A3/4 and NY-ESO1 were used for immunohistochemical staining. Results were classified as follows: no positive tumor cells (-), slightly expressed (+) if <10% of tumor cells were positive, moderately expressed (++) if 10%-50% of tumor cells were positive, and strongly positive (+++) if >50% of tumor cells were stained. Results were analyzed using Mann-Whitney test and Spearman's rank correlation coefficient ; P<0.05 was considered to be statistically significant. The median of age of RO patients was 65 (range 47-80) years, with tumor size median of 3 (range 0.9-8) cm. The median of age of CRCC patients was 58 (range 34-76) years, with median CRCC size of 6.9 (range 1.7-12) cm. Median MAGE-A3/4 expression was (++) in RO and (-) in CRCC. The difference in MAGE-A3/4 expression between the tumors was significant (P=0.0013). Median NY-ESO1 expression was (+++) in RO and (-) in CRCC. The difference in NY-ESO1 expression between the tumors was also significant (P=0.0008). RO had a significantly higher expression of both antigens. Comparison of the prognostic markers of CRCC (size, grade) with the expression of MAGE-A3/4 and NY-ESO1 antigens showed that there was no significant correlation between antigen expression and these prognostic markers. The same was found on comparing the expression of MAGE-A3/4 and NY-ESO1 antigens with the size of RO. However, significant correlation was found between the expression of MAGE-A3/4 and NY-ESO1 antigens in both tumors: r=0.87 (P=0.0003) for RO and r=0.93 (P=0.0001) for CRCC. This study demonstrated a statistically significant difference in the expression of MAGE-A3/4 and NY- ESO1 antigens between RO and CRCC. Study results also showed the expression of MAGE-A3/4 and NY- ESO1 antigens not to correlate with other prognostic markers in CRCC, however, additional research is needed to explore their potential diagnostic and therapeutic implications.

chromophobe renal cell carcinoma; renal oncocytoma

nije evidentirano